Patients with multivessel disease and unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) derive as much benefit from fractional flow reserve (FFR)-guided percutaneous coronary ...

Characteristics of STEMI Reperfusion Systems Identified Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor ...

Bethesda, MD and Dallas, TX - The American College of Cardiology (ACC) and the American Heart Association (AHA) have updated practice guidelines to hone the management of patients with unstable angina ...

The 2011 focused update was published online March 28, 2011, ahead of print in the Journal of the American College of Cardiology and Circulation. The writing committee, led by R. Scott Wright, MD, of ...

Ticagrelor (Brilinta, AstraZeneca) gains equal standing with prasugrel (Effient, Lilly) and clopdiogrel in the newly released focused update of the ACCF/AHA guidelines for unstable angina and ...

Oral anti-platelet therapy Effient (prasugrel) has been added to the updated clinical practice guidelines as a class I recommended treatment option for patients undergoing Percutaneous Coronary ...

Background and Purpose: Since 2000, when these guidelines were last issued, there have been rapid advances in antiplatelet, antithrombotic, and cholesterol-lowering therapy, along with further ...

In draft guidance published today for consultation, NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare) as an option for preventing blood clots in people who have had a heart attack as a ...

Since the start of 2011, the active ingredient ticagrelor can be prescribed in Germany in addition to acetylsalicylic acid to avoid blood clots in patients with acute ischaemia of the cardiac muscle.

Individuals with diabetes and acute coronary syndromes (ACS) such as a heart attack or unstable angina have an increased risk of death at 30 days and one year after ACS, compared with ACS patients ...

PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended ...

Since the start of 2011, the active ingredient ticagrelor can be prescribed in Germany in addition to acetylsalicylic acid (ASA) to avoid blood clots in patients with acute ischaemia of the cardiac ...